PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26223482-9	2016	CONCLUSIONS: Hyperbilirubinemia develops at early time points after simeprevir administration in most cases and is dependent on the ITPA genotype.	Simeprevir	68-78	inosine triphosphatase	Homo sapiens	132-136	
26916827-0	2016	Effects of ITPA polymorphism on decrease of hemoglobin during simeprevir, peg-interferon, and ribavirin combination treatment for chronic hepatitis C. AIM: Polymorphisms in the ITPA gene influence anemia during peg-interferon (PEG-IFN) and ribavirin (RBV) therapy, but their effects during triple therapy with simeprevir, PEG-IFN, and RBV are not sufficiently known.	Simeprevir	62-72	inosine triphosphatase	Homo sapiens	11-15	
26916827-0	2016	Effects of ITPA polymorphism on decrease of hemoglobin during simeprevir, peg-interferon, and ribavirin combination treatment for chronic hepatitis C. AIM: Polymorphisms in the ITPA gene influence anemia during peg-interferon (PEG-IFN) and ribavirin (RBV) therapy, but their effects during triple therapy with simeprevir, PEG-IFN, and RBV are not sufficiently known.	Simeprevir	62-72	inosine triphosphatase	Homo sapiens	177-181	
26916827-0	2016	Effects of ITPA polymorphism on decrease of hemoglobin during simeprevir, peg-interferon, and ribavirin combination treatment for chronic hepatitis C. AIM: Polymorphisms in the ITPA gene influence anemia during peg-interferon (PEG-IFN) and ribavirin (RBV) therapy, but their effects during triple therapy with simeprevir, PEG-IFN, and RBV are not sufficiently known.	Simeprevir	310-320	inosine triphosphatase	Homo sapiens	177-181	
26916827-5	2016	In simeprevir plus PEG-IFN/RBV-treated patients, decreases in hemoglobin levels were faster and greater, and the cumulative proportion of patients with ribavirin dose reduction was significantly greater in ITPA genotype CC patients than in CA/AA patients.	Simeprevir	3-13	inosine triphosphatase	Homo sapiens	206-210	
26916827-9	2016	CONCLUSION: ITPA polymorphism influences hemoglobin levels and incidence of RVB dose reduction during simeprevir triple therapy, indicating the importance of monitoring anemia during treatment, particularly for ITPA genotype CC patients.	Simeprevir	102-112	inosine triphosphatase	Homo sapiens	12-16